Dimerix (ASX:DXB) Net Margin %: -754.23% (As of Dec. 2025)


ASX:DXB Dimerix Ltd ASX:DXB
32 GF Score
Price A$0.20
! 3 Warning Signs
View Full Analysis

What is Dimerix Net Margin %?

Dimerix ASX:DXB +2.56% 32 Net Margin % is -754.23% as of Dec. 2025. GuruFocus rates ASX:DXB with a GF Score™ of 32/100. The stock has 3 warning signs investors should review. Among 947 Biotechnology companies, Dimerix ranks worse than 61.56% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Dimerix's Net Income for the six months ended in Dec. 2025 was A$-15.97 Mil. Dimerix's Revenue for the six months ended in Dec. 2025 was A$2.12 Mil. Therefore, Dimerix's net margin for the quarter that ended in Dec. 2025 was -754.23%.

The historical rank and industry rank for Dimerix's Net Margin % or its related term are showing as below:

ASX:DXB' s Net Margin % Range Over the Past 10 Years
Min: -4195.33   Med: -2216.26   Max: -219.94
Current: -219.94

ASX:DXB's Net Margin % is ranked worse than
61.56% of 947 companies
in the Biotechnology industry
Industry Median: -89.33 vs ASX:DXB: -219.94

Dimerix  (ASX:DXB) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Dimerix Net Margin % Related Terms

Dimerix Net Margin % Historical Data

* Premium members only.

The historical data trend for Dimerix's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dimerix Net Margin % Chart

Dimerix Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 -4,195.33 -237.19

Dimerix Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5,017.29 -3,796.35 -4,497.21 -6.49 -754.23

ASX:DXB vs VRTX, REGN, ALNY: Net Margin % Comparison

For the Biotechnology subindustry, Dimerix's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Dimerix Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Dimerix's Net Margin % distribution charts can be found below:

* The bar in red indicates where Dimerix's Net Margin % falls into.


ASX:DXB
32GF Score
Dimerix Ltd ASX:DXB
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Dimerix Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Dimerix's Net Margin for the fiscal year that ended in Jun. 2025 is calculated as

Net Margin=Net Income (A: Jun. 2025 )/Revenue (A: Jun. 2025 )
=-13.252/5.587
=-237.19 %

Dimerix's Net Margin for the quarter that ended in Dec. 2025 is calculated as

Net Margin=Net Income (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-15.967/2.117
=-754.23 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of -754.23% mean?
Dimerix (ASX:DXB) has a Net Margin % of -754.23% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Dimerix and its competitors. According to the industry distribution chart, Dimerix ranks #583 out of 947 companies in the Biotechnology industry, placing it in the top 61.6%.
Is Dimerix's Net Margin % too high?
Dimerix's current Net Margin % is -754.23%. Based on the distribution chart, Dimerix ranks #583 out of 947 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Dimerix has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Dimerix's Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Dimerix ranks #583 out of 947 companies for Net Margin %. This places Dimerix in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Dimerix and its competitors. Dimerix's current Net Margin % is -754.23%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dimerix stock overvalued right now?
Dimerix (ASX:DXB) has a current Net Margin % of -754.23%. The current Net Margin % is -754.23%. Dimerix's overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Dimerix (ASX:DXB), the current Net Margin % is -754.23% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Dimerix Business Description

Address 425 Smith Street, Fitzroy, VIC, AUS, 3065
Dimerix Ltd is a biopharmaceutical company developing new therapies in areas with unmet medical needs. The company is developing four product candidates: DMX-200 for FSGS; DMX-200 for diabetic kidney disease; DMX-200 for ARDS associated with COVID-19; and DMX-700 for COPD, as well as the proprietary ReceptorHIT assay technology. It pursues new product concepts and applies deep scientific knowledge to the discovery of products from early-stage development through to commercialisation. Dimerix products will target multiple territories. The Group has only operated in one Segment, being investment in research and development of biopharmaceutical drugs.
32GF Score

Get the complete analysis for ASX:DXB

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.20
Price